International Niemann–Pick Disease Alliance
17 July 2019 Dear Global Community of NPC Patients, Families, Friends and Supporters, I am writing to personally share the news that I will be resigning my position as Orphazyme’s Chief Executive Officer effective October 1, 2019....
ALACHUA, FL – (BusinessWire) – July 08, 2019 – CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, today announced the appointment of Mr. Michael...
Orphazyme to prepare for filing of arimoclomol in Europe for Niemann-Pick disease Type C (NPC) • Expected submission of Marketing Authorization Application (MAA) in H1 2020 Copenhagen, June 7, 2019 – Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company dedicated...
ALACHUA, FL / ACCESSWIRE / May 31, 2019 / CTD Holdings, Inc. (OTCQB: CTDH)(“CTD” or the “Company”), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, today announced that it closed...
ALACHUA, FL – (Accesswire) – May 23, 2019 – CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, today announced its first home-based infusion of...
ALACHUA, FL – (Accesswire) – May 16, 2019 – CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, today announced that company representatives will attend...
International Niemann Pick Disease Alliance 6th Biennial “Face to Face” Meeting 14-16 June 2019 Radisson Blu Hotel Lyon 129 Rue Servient, 69003 Lyon, France https://www.radissonblu.com/en/hotel-lyon We are pleased to announce that the 6th Biennial INPDA Face-to-Face Meeting...
Program is open to two patients who completed CTD’s clinical trial with Trappsol® Cyclo™ in the United States ALACHUA, FL – (Accesswire) – May 07, 2019 – CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage...
My name is Raphaël Beaugillet, I come from France and I am a friend of Alix (age 36) and Zita (age 30) both of whom are affected by the ultra-rare Niemann-Pick-C disease (NP-C). I will participate in the Road...
ALACHUA, FL – (Globe Newswire) – March 14, 2019 – CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, announced today that the company has...